Reports from the Field: One-week therapy heals H. pylori ulcers
Reports from the Field
One-week therapy heals H. pylori ulcers
Esomeprazole, the first proton pump inhibitor (PPI) developed as an isomer, effectively eradicates Heliobacter pylori when combined with two antibiotics and heals duodenal ulcers without the need for follow-up PPI monotherapy, reducing the treatment period from four weeks to one for patients with H. pylori-associated duodenal ulcers, according to data presented at the European Helicobacter Pylori Study Group workshop held recently in Rome.
Results of the two multi-center studies demonstrate that 20 mg of esomeprazole twice daily in seven-day triple therapy with the standard antibiotics amoxicillin and clarithromycin twice daily, effectively eradicates H. pylori in 90% of patients. In addition, researchers found that use of seven-day esomeprazole triple therapy heals associated duodenal ulcers in more than 90% of patients, eliminating the need for three-week follow-up monotherapy.
Esomeprazole is manufactured under the brand name Nexium by AstraZeneca in Wilmington, DE. For more information on esomeprazole, visit the Nexium interactive Web site at www.nexiumpressoffice.com.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.